Mineralys Therapeutics (MLYS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.53
- Surprise
- —
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Mineralys Therapeutics Q2 EPS $(2.85) Misses $(0.55) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates MLYS Sell at 4.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Pipeline: lorundrostat
- Quality below floor (1.6 < 4.0)
- Momentum score 2.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $15.99
- Price target
- $39.34
- Stop
- $14.87
- Upside to target
- +146.0%
- Reward-to-risk
- 9.7:1
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
MLYS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.41B
- P/E (fwd)
- -6.7
- 52-week range
- $15.34–$47.65
- Off 52-week high
- 66.4%
- RSI (14)
- 31
- Volume vs avg
- 1.47×
- Score today
- 4.9/10